Edison Investment Research - Numis Corp. PLC (NUM) Numis Corporation - Very strong results, consistent strategy

Report

Edison Investment Research

Pedro Fonseca

Numis Corporation - Very strong results, consistent strategy

In addition to successfully executing a high volume of transactions for clients in the first half, Numis continues to plan investment to strengthen and broaden its capabilities to support longer-term growth through market cycles. With over 60% of transaction fee income in H120 coming from outside the retained client base there is evidence that the company is succeeding in building a wider reputation.

13/05/2021 13 EN

Underlying

Numis Corp. PLC

Numis Corp. is a holding company. Co. is an independent institutional stockbroker and corporate advisor. Co. is a provider of access to capital for U.K. listed companies. Co. provides a range of research, execution, corporate broking and advisory services to companies of all sizes quoted in the U.K. and their investors. Co. serves a range of corporate clients across 16 sectors.

See profile

GB00B05M6465 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Pedro Fonseca

Other Reports on these Companies

EQS Group AG

Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - Numis Corporation PLC

Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - Numis Corporation PLC 19-May-2023 / 14:52 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton UK Dividend Trust PLC and MI Chelverton UK Equity Income Fund (b) Owner or controller of interests and short positions disclosed, if different from 1(a...

May 19, 2023 May 19, 2023 1 EN

EQS Group AG

Form 8.3 - Maitland Institutional Services Limited: Re Numis Corporation plc - AMENDED

Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Numis Corporation plc - AMENDED 11-May-2023 / 17:13 GMT/BST FORM 8.3 AMENDMENT TO SECTION 1(e) AND 3(a) OF FORM 8.3 RELEASED AT 13:25 ON 10 MAY 2023 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton UK Dividend Trust PLC and MI Chelverton UK Equity Income Fund ...

May 11, 2023 May 11, 2023 1 EN

EQS Group AG

Form 8.3 - Maitland Institutional Services Limited: Numis Corporation Plc

Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Numis Corporation Plc 10-May-2023 / 13:25 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton UK Dividend Trust PLC and MI Chelverton UK Equity Income Fund (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The...

May 10, 2023 May 10, 2023 1 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

16h / 18m 16h / 18m 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

18h / 12m 18h / 12m 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

19h / 39m 19h / 39m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Numis Corporation - Very strong results, consistent strategy

Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - Numis Corporation PLC

Form 8.3 - Maitland Institutional Services Limited: Re Numis Corporation plc - AMENDED

Form 8.3 - Maitland Institutional Services Limited: Numis Corporation Plc

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

AAC Clyde Space - Solid start to the year with further order growth

Tinexta - Typical seasonality in Q124

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe